Sudeep Pharma Limited (BOM:544619)
India · Delayed Price · Currency is INR 1,111.10
-1.50 (-0.13%)
At close: Aug 21, 2026
Sudeep Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 6,756 | 6,423 | 5,020 | 4,593 | 4,287 | 3,446 |
| 6,756 | 6,423 | 5,020 | 4,593 | 4,287 | 3,446 | |
Revenue Growth | 31.84% | 27.94% | 9.30% | 7.12% | 24.41% | 4999.06% |
Cost of Revenue | 2,452 | 2,309 | 1,677 | 1,676 | 1,868 | 1,376 |
Gross Profit | 4,304 | 4,113 | 3,343 | 2,917 | 2,420 | 2,070 |
Selling, General & Admin | 588.06 | 567.04 | 416.63 | 345.8 | 679.74 | 721.28 |
Other Operating Expenses | 1,384 | 1,325 | 1,027 | 751.74 | 831.86 | 660.83 |
Operating Expenses | 2,130 | 2,042 | 1,549 | 1,188 | 1,607 | 1,429 |
Operating Income | 2,174 | 2,071 | 1,794 | 1,729 | 812.88 | 640.66 |
Interest Expense | -74.55 | -71.01 | -54.59 | -38.2 | -45.82 | -14.69 |
Interest & Investment Income | 33.79 | 33.79 | 1.37 | 1.22 | 0.97 | 0.72 |
Currency Exchange Gain (Loss) | 239.56 | 239.56 | 80.9 | 49.7 | 82.73 | 55.84 |
Other Non Operating Income (Expenses) | -0.43 | -3.3 | -3.23 | 1.4 | 9.55 | -4.37 |
EBT Excluding Unusual Items | 2,372 | 2,270 | 1,818 | 1,744 | 860.31 | 678.16 |
Gain (Loss) on Sale of Investments | 1.21 | 1.21 | 0.09 | 0.94 | 0.33 | 0.51 |
Gain (Loss) on Sale of Assets | - | - | -0.41 | 0.02 | -0.84 | -0.03 |
Other Unusual Items | 8.74 | 8.74 | 8.41 | - | - | - |
Pretax Income | 2,383 | 2,281 | 1,828 | 1,748 | 859.8 | 685.35 |
Income Tax Expense | 546.93 | 537.9 | 441.16 | 416.08 | 236.59 | 187.36 |
Earnings From Continuing Operations | 1,836 | 1,743 | 1,387 | 1,332 | 623.21 | 497.99 |
Minority Interest in Earnings | -9.67 | -13.92 | - | - | - | - |
Net Income | 1,826 | 1,729 | 1,387 | 1,332 | 623.21 | 497.99 |
Net Income to Common | 1,826 | 1,729 | 1,387 | 1,332 | 623.21 | 497.99 |
Net Income Growth | 33.68% | 24.63% | 4.14% | 113.75% | 25.14% | 36106.24% |
Shares Outstanding (Basic) | 113 | 112 | 109 | 109 | 109 | 109 |
Shares Outstanding (Diluted) | 113 | 112 | 109 | 109 | 109 | 109 |
Shares Change | 3.47% | 2.80% | - | - | - | 361.48% |
EPS (Basic) | 16.21 | 15.50 | 12.79 | 12.28 | 5.74 | 4.59 |
EPS (Diluted) | 16.21 | 15.50 | 12.79 | 12.28 | 5.74 | 4.59 |
EPS Growth | 29.18% | 21.23% | 4.14% | 113.89% | 25.06% | 7745.71% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | -158.25 | -155.06 | 157 | 12.42 | -603.93 |
Free Cash Flow Per Share | - | -1.42 | -1.43 | 1.45 | 0.11 | -5.57 |
Dividend Per Share | 1.500 | 1.500 | - | - | - | - |
Dividend Growth | - | - | - | - | - | - |
Gross Margin | 63.71% | 64.04% | 66.60% | 63.52% | 56.44% | 60.06% |
Operating Margin | 32.18% | 32.25% | 35.74% | 37.66% | 18.96% | 18.59% |
Profit Margin | 27.03% | 26.92% | 27.63% | 29.00% | 14.54% | 14.45% |
Free Cash Flow Margin | - | -2.46% | -3.09% | 3.42% | 0.29% | -17.52% |
EBITDA | 2,316 | 2,209 | 1,891 | 1,813 | 887.29 | 685.36 |
EBITDA Margin | 34.28% | 34.39% | 37.66% | 39.48% | 20.70% | 19.89% |
D&A For EBITDA | 142.16 | 137.88 | 96.58 | 83.92 | 74.41 | 44.7 |
EBIT | 2,174 | 2,071 | 1,794 | 1,729 | 812.88 | 640.66 |
EBIT Margin | 32.18% | 32.25% | 35.74% | 37.66% | 18.96% | 18.59% |
Effective Tax Rate | 22.95% | 23.58% | 24.13% | 23.80% | 27.52% | 27.34% |
Revenue as Reported | 7,045 | 6,708 | 5,113 | 4,654 | 4,383 | 3,510 |
Advertising Expenses | - | 0.49 | 0.04 | 24.76 | 9.41 | 4.57 |